Bristol Myers Squibb is projected to deliver low‐double‐digit revenue growth in Q4 2025, driven primarily by continued strength in Opdivo and recent launches in hematology. Wall Street consensus anticipates mid‐teens percentage growth in oncology revenues, with Opdivo sales expected to exceed $3.5 billion for the quarter, representing roughly 18 % year‐over‐year growth. Non‐GAAP EPS is forecast to land near $1.70, underpinned by operating leverage in high‐margin immuno‐oncology products and anticipated cost savings from supply‐chain efficiencies. Investors are also watching the contribution from Reblozyl and Camzyos, which together may add another $400 million in Q4 revenue and help offset margin pressures elsewhere.

While Opdivo accelerates, legacy small‐molecule franchises such as Eliquis and Orencia are expected to face revenue declines of 5 %–7 % due to increased generic competition. Management has highlighted that branded immunology assets like Orencia could see mid‐single‐digit volume gains, but pricing concessions and biosimilar entries are likely to trim overall revenue. In response, R&D spending is slated to rise by 10 %, with late‐stage trials for the BCMA bispecific antibody and the CELMoD compound seeking to bolster the pipeline and drive long‐term growth.

Recent 13F filings show institutional investors increasing their stakes in the stock: Capital Management Corp VA added 9 615 shares in Q3 2025, lifting its total holding to 111 670 shares (up 9.6 % quarter‐over‐quarter). Charles Schwab Investment Management grew its position by 16.8 %, now holding more than 70 million shares, while Arrowstreet Capital more than quintupled its stake to over 11 million shares during the same period. Overall, institutional ownership stands at approximately 76 %, underscoring continued confidence from large asset managers ahead of the earnings release.